

Grindeks AS (GRD1R) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/G0F5A0DB93CEN.html>

Date: September 2020

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: G0F5A0DB93CEN

Abstracts

Grindeks AS (GRD1R) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grindeks focuses on the research, development, manufacture and marketing of original products, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and anti-diabetes therapeutic categories. The company provides final dosage form pharmaceutical products ranging from solid form products, solution for injections to syrups and ointments. Grindeks also provides regulatory, analytical and final dosage form contract manufacturing services to pharmaceutical companies. Through subsidiaries and representative offices, the company markets its products in the European (EU) countries, the US, Canada, Russia and other CIS countries, Japan and Vietnam. Grindeks operates subsidiary companies in Latvia, Estonia and Slovakia and is headquartered in Riga, Latvia.

Grindeks AS Key Recent Developments

Aug 27,2020: Grindeks: Results in the first half of 2020

Apr 30,2020: Grindeks Group publishes audited consolidated financial statements for 2019

Feb 28,2020: On Grindeks results in 2019

Feb 04,2020: Juris Hmelnickis appointed as the Chairman of the Board of Grindeks

Dec 19,2019: JSC Grindeks receives a certificate of Saudi Food and Drug Authority

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Grindeks AS - Key Facts
Grindeks AS - Key Employees
Grindeks AS - Key Employee Biographies
Grindeks AS - Major Products and Services
Grindeks AS - History
Grindeks AS - Company Statement
Grindeks AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Grindeks AS - Business Description
Business Segment: Active Pharmaceutical Ingredients
Overview
Performance
Business Segment: Final Dosage Forms
Overview
Performance
Geographical Segment: Estonia
Performance
Geographical Segment: Latvia
Performance
Geographical Segment: Lithuania
Performance
Geographical Segment: Other CIS Countries
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: Russia
Performance
Grindeks AS - Corporate Strategy
Grindeks AS - SWOT Analysis
SWOT Analysis - Overview

Grindeks AS - Strengths
Grindeks AS - Weaknesses
Grindeks AS - Opportunities
Grindeks AS - Threats
Grindeks AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grindeks AS, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 27, 2020: Grindeks: Results in the first half of 2020
Apr 30, 2020: Grindeks Group publishes audited consolidated financial statements for 2019
Feb 28, 2020: On Grindeks results in 2019
Feb 04, 2020: Juris Hmelnickis appointed as the Chairman of the Board of Grindeks
Dec 19, 2019: JSC Grindeks receives a certificate of Saudi Food and Drug Authority
Aug 29, 2019: Grindeks: results in the first six months of 2019
May 30, 2019: On “Grindeks” results in the first three months of 2019
May 14, 2019: JSC “Grindeks” Group could reach 300 million euro turnover within five years
Apr 30, 2019: Grindeks announced audited results in 2018
Mar 01, 2019: Turnover of Grindeks reaches 145.5 million euros in 2018

SECTION 6 – APPENDIX

Methodology

[Ratio Definitions](#)
[About GlobalData](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Grindeks AS, Key Facts
Grindeks AS, Key Employees
Grindeks AS, Key Employee Biographies
Grindeks AS, Major Products and Services
Grindeks AS, History
Grindeks AS, Other Locations
Grindeks AS, Subsidiaries
Grindeks AS, Key Competitors
Grindeks AS, Ratios based on current share price
Grindeks AS, Annual Ratios
Grindeks AS, Annual Ratios (Cont...1)
Grindeks AS, Annual Ratios (Cont...2)
Grindeks AS, Interim Ratios
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grindeks AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grindeks AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Grindeks AS, Performance Chart (2015 - 2019)

Grindeks AS, Ratio Charts

Grindeks AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Grindeks AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Transgene SA

Sopharma AD

Olainfarm AS

Napp Pharmaceuticals Ltd

Dokumeds

Baxter Oncology GmbH

AmberCRO

I would like to order

Product name: Grindeks AS (GRD1R) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/G0F5A0DB93CEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0F5A0DB93CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970